Other · developed by PFIZER
PF-07832837 is an investigational agent studied in healthy participants and in atopic dermatitis, given at escalating doses.
Summary written with AI from the sources listed at the end of this page.
Atopic DermatitisHealthy Participants
Updated Nov 8, 2026. Something wrong or missing? Report it on the PFE page.
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →